Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

How Data Analytics Transforms Biotech Firms: A Consultant's Perspective

May 14, 2026

Introduction to Data Analytics in Biotech

In the rapidly evolving world of biotechnology, data analytics is proving to be a game-changer. As biotech firms strive to innovate and stay ahead of the competition, utilizing data analytics offers unparalleled insights and opportunities for growth. From drug discovery to personalized medicine, data analytics is at the heart of modern biotech advancements.

biotech data analysis

Enhancing Research and Development

One of the most significant impacts of data analytics in biotech is in research and development (R&D). By analyzing large datasets, biotech companies can identify potential drug candidates more efficiently. Advanced algorithms enable researchers to simulate biological processes, reducing the time and cost associated with laboratory experiments. This not only speeds up the discovery process but also increases the likelihood of successful outcomes.

Furthermore, data analytics allows for the integration of various data sources, providing a holistic view of research projects. This integration facilitates better decision-making and strategic planning, ultimately leading to more innovative solutions.

Streamlining Clinical Trials

Clinical trials are an essential component of bringing new biotech products to market. Traditionally, these trials are time-consuming and expensive. However, data analytics helps streamline the process by identifying suitable candidates, predicting outcomes, and monitoring ongoing trials in real-time.

clinical trials data

With predictive analytics, firms can assess potential risks and make informed adjustments to trial protocols. This proactive approach not only increases the efficiency of trials but also enhances patient safety and regulatory compliance.

Personalized Medicine and Patient Care

Data analytics is transforming the approach to personalized medicine, allowing for treatments tailored to individual patients. By analyzing genetic, environmental, and lifestyle data, biotech firms can develop therapies that are more effective and have fewer side effects.

This patient-centric approach improves outcomes and provides patients with treatments that are specifically designed for their unique genetic makeup. As a result, data-driven personalized medicine is becoming a cornerstone of modern healthcare.

personalized medicine

Optimizing Operational Efficiency

Beyond R&D and clinical trials, data analytics is also enhancing operational efficiency within biotech firms. By analyzing supply chain data, companies can optimize production schedules, reduce waste, and improve resource allocation.

  • Improved inventory management
  • Enhanced forecasting and demand planning
  • Streamlined logistics and distribution

These improvements contribute to a more sustainable and cost-effective operation, allowing biotech firms to allocate resources to other critical areas.

Conclusion: The Future of Biotech with Data Analytics

As data analytics continues to advance, its impact on the biotech industry will only grow stronger. Firms that embrace these technologies are better positioned to innovate, improve patient outcomes, and maintain a competitive edge. From R&D to personalized medicine, data analytics is paving the way for a new era in biotechnology.

For consultants working in this field, understanding the capabilities and potential of data analytics is essential. By leveraging these tools, consultants can guide biotech firms towards more strategic, data-driven decisions that lead to success.